secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001558370-25-010176
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Pharma Q2 revenue $48.5M (+29% seq), net loss $(48.0M); advances setmelanotide filings for AHO
--------------------------------------------------------------------------------

- Q2 net product revenue $48.5M, up 29% sequentially from Q1 2025; US revenue $32.0M (66% of total), up 31%.
- Net loss $(48.0)M ($(0.75)/share) vs $(33.6)M ($(0.55)/share) in Q2 2024.
- Cash $291M at June 30; added ~$189.2M from July stock offering; paid $40M to LG Chem for bivamelagon.
- Phase 3 TRANSCEND: setmelanotide achieved placebo-adjusted BMI reduction of -19.8% in acquired hypothalamic obesity (AHO).
- Regulatory submissions for setmelanotide in AHO to FDA and EMA on track for Q3 2025; FY 2025 Non-GAAP OpEx guidance $285-315M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000155837025010176/0001558370-25-010176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000155837025010176/rytm-20250805x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-010176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer